Gemin X Pharmaceuticals: Finding A Drug's Mechanism Of Action

Gemin X, a pharmaceutical company focused on the discovery and development of advanced oncology therapeutics, approached Metabolon to run a metabolism profile for one of their compounds—GMX1777.

The pro-drug GMX1777, is converted to GMX1778, the active compound which has strong anti-tumor activity in animal and cell culture models, and induces cell death in cells within 48-72 hours in vitro. After initial work performed by Gemin X using genomic, proteomic and biochemical methods, the mechanism of action was still unclear but possible anti-metabolic activity was suggested.

Working with Metabolon’s project team, Gemin X designed a simple cell culture time course study to give mechanistic insight into this promising new drug.